Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation 1

British Journal of Anaesthesia

Volumn 76, Issue 5, 1996, Pages 624-628

  De Wolf, Andre M ^a,c   Freeman, Judith A ^a   Scott, Victor L ^a   Tullock, William ^a   Ryan Cook, D ^a   Smith, Deborah A ^b   Kisor, David F ^b   Kerls, Susam ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Liver, disease; Liver, transplantation; Neuromuscular block, 51W89; Neuromuscular block, atracurium; Pharmacodynamics; Pharmacokinetics, 51W89; Pharmacokinetics, atracurium; Pharmacokinetics, stereoisomers

Indexed keywords

ATRACURIUM; CISATRACURIUM; LAUDANOSINE; NEUROMUSCULAR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; ELECTROMYOGRAPHY; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; NERVE STIMULATION; NEUROMUSCULAR BLOCKING; PRIORITY JOURNAL; ULNAR NERVE;

ADULT; AGED; ATRACURIUM; EVOKED POTENTIALS; FEMALE; HALF-LIFE; HUMANS; ISOMERISM; ISOQUINOLINES; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEUROMUSCULAR JUNCTION; NEUROMUSCULAR NONDEPOLARIZING AGENTS; TIME FACTORS;

EID: 0029988636     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/76.5.624     Document Type: Article

References (20)

1. Belmont MR, Lien CA, Quessy S, Abou-Donia MM, Abalos A, Eppich L, Savarese JJ. The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995; 82: 1139-1145.
2. Boyd AH, Eastwood NB, Parker CJR, Hunter JM. Pharmacodynamics of the 1R cis-1′R cis isomer of atracurium (51W89) in health and chronic renal failure. British Journal of Anaesthesia 1995; 74: 400-404.
3. Ornstein E, Lien C, Matteo RS, Ostapkovich N, Wolf K, Kisor D, Diaz J. Pharmacodynamics and pharmacokinetics of 51W89 in geriatric surgical patients. Anesthesiology 1994; 81: A1076.
4. Lepage JY, Malinovsky JM, Malinge M, Cozian A, Pinaud M. Comparison of equipotent doses of 51W89 and atracurium. Anesthesiology 1994; 81: A1090.
5. Lien CA, Belmont MR, Abalos A, Eppich L, Quessy S, Abou-Donia MM, Savarese JJ. The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995; 82: 1131-1138.
6. Welch RM, Brown A, Ravitch J, Dahl R. The in vitro degradation of cisatracurium, the R, cis-R′-isomer of atracurium, in human and rat plasma. Clinical Pharmacology and Therapeutics 1995; 58: 132-142.
7. Stiller RL, Cook DR, Chakravorti S. In vitro degradation of atracurium in human plasma. British Journal of Anaesthesia 1985; 57: 1085-1088.
8. Ward S, Weatherley BC. Pharmacokinetics of atracurium and its metabolites. British Journal of Anaesthesia 1986; 58: 6S-10S.
9. Kisor DF, Wargin WA, Schmith VD, Cook DR, Ornstein E. Organ-independent Hofmann elimination is the major clearance pathway of the neuromuscular blocking agent 51W89 in man. Pharmaceutical Research 1994; 11: S335.
10. Verotta D, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmacodynamics : an improved algorithm. Computer Applications in the Biosciences 1987; 3: 345-349.
11. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clinical Pharmacology and Therapeutics 1979; 25: 358-371.
12. Nakashima E, Benet LZ. General treatment of mean residence time, clearance, and volume parameters in linear mamillary models with elimination from any compartment. Journal of Pharmacokinetics and Biopharmaceutics 1988; 16: 475-492.
13. Lien CA, Schmith VD, Belmont MR, Kisor D, Savarese JJ. Pharmacokinetics/dynamics of 51W89 in healthy patients during opioid anesthesia. Anesthesiology 1994; 81: A1082.
14. Ward S, Neill EAM. Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure). British Journal of Anaesthesia 1983; 55: 1169-1172.
15. Cook DR, Brandom BW, Stiller RL, Woelfel S, Lai A, Slater J. Pharmacokinetics of atracurium in normal and liver failure patients. Anesthesiology 1984; 61: A433.
16. Parker CJR, Hunter JM. Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis. British Journal of Anaesthesia 1989; 62: 177-183.
17. Shearer ES, O'Sullivan EP, Hunter JM. Clearance of atracurium and laudanosine in the urine and by continuous venovenous haemofiltration. British Journal of Anaesthesia 1991; 67: 569-573.
18. Bell CF, Hunter JM, Jones RS, Utting JE. Use of atracurium and vecuronium in patients with oesophageal varices. British Journal of Anaesthesia 1985; 57: 160-168.
19. Bion JF, Bowden MI, Chow B, Honisberger L, Weatherley BC. Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation. Intensive Care Medicine 1993; 19 (Suppl. 2): S94-S98.
20. Vandenbrom RHG, Wierda JMKH, Agoston S. Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. Clinical Pharmacokinetics 1990; 19: 230-240.